L’anticorps anti-CCR2 (Plozalizumab Biosimilar) Monoclonal Mammalian Cells est utilisé pour la détection de CCR2 (Plozalizumab Biosimilar) dans des échantillons de Humain. Il a été validé pour ELISA.
MLN-1202,anti-CCR2,hu1D9 Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in the trafficking of monocytes and macrophages to sites of inflammation.